Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Abeona Therapeutics Inc. (ABEO)

4.05   -0.16 (-3.8%) 10-02 16:00
Open: 4.27 Pre. Close: 4.21
High: 4.44 Low: 4.02
Volume: 147,738 Market Cap: 100(M)

Technical analysis

as of: 2023-10-02 4:48:01 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 4.89     One year: 5.31
Support: Support1: 3.59    Support2: 2.99
Resistance: Resistance1: 4.18    Resistance2: 4.55
Pivot: 3.93
Moving Average: MA(5): 4.03     MA(20): 3.98
MA(100): 3.79     MA(250): 3.41
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 50.7     %D(3): 48.6
RSI: RSI(14): 53.2
52-week: High: 5.8  Low: 2.19
Average Vol(K): 3-Month: 136 (K)  10-Days: 163 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ABEO ] has closed below upper band by 35.3%. Bollinger Bands are 26% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.45 - 4.47 4.47 - 4.49
Low: 3.96 - 3.99 3.99 - 4.01
Close: 4 - 4.04 4.04 - 4.08

Company Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Headline News

Fri, 29 Sep 2023
Insider Transaction CEO of Abeona Therapeutics Purchases 20000 ... - Best Stocks

Tue, 26 Sep 2023
Abeona Therapeutics Submits BLA for Groundbreaking RDEB ... - Best Stocks

Mon, 18 Sep 2023
Where Does Abeona Therapeutics Inc (ABEO) Stock Fall in the Biotechnology Field After It Is Down -12.76% This Week? - InvestorsObserver

Wed, 06 Sep 2023
Should You Buy Abeona Therapeutics Inc (ABEO) in Biotechnology Industry? - InvestorsObserver

Mon, 21 Aug 2023
Will Abeona Therapeutics Inc (ABEO) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Fri, 18 Aug 2023
Should You Buy Abeona Therapeutics Inc (ABEO) Stock After it Is Higher By 22.41% in a Week? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 25 (M)
% Held by Insiders 1.862e+007 (%)
% Held by Institutions 6.7 (%)
Shares Short 538 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.224e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 261.8
Return on Equity (ttm) -57.3
Qtrly Rev. Growth 3.57e+006
Gross Profit (p.s.) 195.31
Sales Per Share -208.73
EBITDA (p.s.) -2.1875e+007
Qtrly Earnings Growth -1.8
Operating Cash Flow 0 (M)
Levered Free Cash Flow -43 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 11.78

Stock Dividends

Dividend 0
Forward Dividend 500540
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.